Overview
EASYDNA AUSTRALIA
Taking an even closer look at DNA, Genetic Technologies examines the building blocks that make up the building blocks of life. The company makes genetic testing products that are focused on women's health. Its BREVAGen
plus
risk assessment test helps physicians determine a woman's likelihood to develop breast cancer. (It was released in late 2014.) US subsidiary Phenogen Sciences provides sales and marketing services and has helped
...
Read More with the launch of BREVAGen. The company was formerly engaged in the research of non-coding DNA, otherwise known as "junk" or excess DNA that does not actively code proteins. It switched its focus to genetic tests addressing cancer because of its higher sales potential.
Read Less
Read More with the launch of BREVAGen. The company was formerly engaged in the research of non-coding DNA, otherwise known as "junk" or excess DNA that does not actively code proteins. It switched its focus to genetic tests addressing cancer because of its higher sales potential.
Read Less
LINDSAY PETER WAKEFIELD
See more contacts
Medical and Diagnostic Laboratories
,
Scientific Research and Development Services
,
Ambulatory Health Care Services
,
Health Care and Social Assistance
,
Medical laboratories
See All Industries , Commercial physical research Holding companies, nec
See Fewer Industries
See All Industries , Commercial physical research Holding companies, nec
See Fewer Industries
Child Care Services
,
Community Food and Housing, and Emergency and Other Relief Services
,
Continuing Care Retirement Communities and Assisted Living Facilities for the Elderly
,
General Medical and Surgical Hospitals
,
Home Health Care Services
,
Individual and Family Services
,
Nursing Care Facilities (Skilled Nursing Facilities)
,
Offices of Dentists
View more , Offices of Other Health Practitioners , Offices of Physicians , Other Ambulatory Health Care Services , Other Residential Care Facilities , Outpatient Care Centers , Psychiatric and Substance Abuse Hospitals , Residential Intellectual and Developmental Disability, Mental Health, and Substance Abuse Facilities , Specialty (except Psychiatric and Substance Abuse) Hospitals Vocational Rehabilitation Services
View fewer
View more , Offices of Other Health Practitioners , Offices of Physicians , Other Ambulatory Health Care Services , Other Residential Care Facilities , Outpatient Care Centers , Psychiatric and Substance Abuse Hospitals , Residential Intellectual and Developmental Disability, Mental Health, and Substance Abuse Facilities , Specialty (except Psychiatric and Substance Abuse) Hospitals Vocational Rehabilitation Services
View fewer
?
?
Estimated
$5.07 million
Actual
-11.76%
$6
JUN
?
?
Australian:GTG
Contacts
Get in Touch with 5 Principals*
-
LINDSAY PETER WAKEFIELDDirector
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of June 30, 2024 (12 month period) in USD
Annual Revenue 2024
$5.07 million
USD
Actual
1 USD = 1.5109 AUD
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | $ | $ | $ |
| Net Investing Cash | $0 | -$0 | -$2 |
| Net Financing Cash | $2 | $4 | -$0 |
| Net Change in Cash | -$4 | -$3 | -$6 |
| Cash at Beginning of Period | $5 | $8 | $14 |
| Cash at End of Period | $1 | $5 | $8 |
| Capital Expenditure | -$0 | -$0 | -$0 |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $1 | $5 | $8 |
| Accounts Receivable | $0 | $0 | $0 |
| Inventories | $0 | $0 | $0 |
| Other Current Assets | $1 | $1 | $1 |
| Asset Summary | |||
| Total Current Assets | $2 | $7 | $10 |
| Tangible Fixed Assets | $0 | $0 | $1 |
| Intangible Assets | $0 | $0 | $0 |
| Total Assets | $6 | $15 | $21 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $1 | $1 | $1 |
| Short-Term Debt | $0 | $ | $ |
| Other Current Liabilities | $1 | $2 | $2 |
| Liability Summary | |||
| Total Current Liabilities | $3 | $2 | $3 |
| Long-Term Debt | $ | $ | $ |
| Other Long-Term Liabilities | $ | $ | $ |
| Total Liabilities | $3 | $2 | $3 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $108 | $107 | $103 |
| Retained Earnings | -$110 | -$104 | -$99 |
| Equity Summary | |||
| Total Equity | $1 | $7 | $11 |
| Shares Outstanding | 132,217,246 | 115,416,581 | 92,339,651 |